Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
  • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
  • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
  • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P33/00—Antiparasitic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
  • A61P35/04—Antineoplastic agents specific for metastasis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

• the present invention relates to compounds with cytotoxic activity consisting of cyclopeptides containing the RGD sequence conjugated to camptothecin derivatives, methods for the preparation thereof, their use as medicaments and compositions containing them.
• the compounds described in the present invention are endowed with both high affinity for integrins ⁇ v ⁇ 3 and ⁇ v ⁇ and selective cytotoxic activity on human cell lines at micromolar concentrations.
• Chemotherapeutic anticancer agents are the drugs with the most restrictive therapeutic window. In fact, since their cytotoxic activity is non-selective they may indiscriminately damage all the cells of the body with which they come into contact.
• the compounds according to the present invention yield medicaments with fewer and less severe side effects.
• the subject of the present invention are camptothecin derivatives conjugated to cyclopeptide derivatives containing the RGD sequence.
• the resulting molecules conserve unaltered both the cytotoxic properties of the original camptothecins and integrin binding properties with affinity comparable to that observed with the non-conjugated cyclopeptides.
• the result of this combination is to favour the concentration of the cytotoxic agent in those cells that most express integrins of the ⁇ v ⁇ 3 and ⁇ v ⁇ type (homing).
• the cytotoxic agent exerts its intracellular activity in the conjugated and/or free form through enzymatic or hydrolytic action.
• the main object of the present invention are compounds of Formula I, as follows:
• i is 0 or 1;
• the compounds of Formula (I) may be prepared by the process described here below and exemplified for the preferred compounds according to the invention. This process constitutes a further subject of the invention.
• the compounds of Formula (I) which are the object of the present invention are prepared by means of the condensation of 7- substituted camptothecins or analogues thereof (indicated as “7-R- CP”), possibly functionalised via a suitable bridge (indicated as "Ui- Xi”), with a cyclopeptide derivative (indicated as "Yi").
• condensation reactions can be carried out according to one of the following reaction schemes:
• 7-R-CP represents a 7-substituted camptothecin or an analogue, in which R has the same meaning as defined in Formula (I)
• Ui, Xi and Yi represent respectively the groups U, X and Y as defined in Formula I, possibly appropriately functionalised and protected so that the conjugated compounds of Formula I are obtained.
• the cyclopeptides Yi can be prepared according to conventional peptide synthesis techniques, as described in examples 4 to 6.
• the peptide synthesis can be accomplished either in the solid phase or in solution.
• the desired cyclopeptide Once the desired cyclopeptide has been obtained, it will be used in the condensation reaction in its protected form, and the protective groups will be removed only after obtaining the final compound.
• the deprotec- tion is done using known methods, e.g. acid conditions by means of the use of pure trifluoroacetic acid or in the presence of chlorinated organic solvents.
• camptothecin derivatives are obtained using methods which are common knowledge to experts of the field.
• the compounds described in the present invention are topoisomerase I inhibitors and are therefore useful as medicaments, particularly for the treatment of diseases that benefit from the inhibition of said topoisomerase.
• the compounds according to the present invention exhibit antiproliferative activity, and therefore are used for their therapeutic properties, and possess physicochemical properties which make them suitable for formulation in pharmaceutical compositions.
• compositions contain at least one compound of Formula (I) as an active ingredient, in an amount such as to produce a significant therapeutic effect.
• the compositions covered by the present invention are entirely conventional and are obtained using methods that are common practice in the pharmaceutical industry. According to the administration route opted for, the compositions will be in solid or liquid form and suitable for oral, parenteral or intravenous administration.
• the compositions according to the present invention contain, along with the active ingredient, at least one pharmaceutically acceptable, vehicle or excipient.
• Formulation adjuvants such as, for example, solubilising agents, dispersing agents, suspension agents or emulsifying agents may be particularly useful.
• the compounds of Formula (I) can also be used in combination with other active ingredients, such as, for example, anticancer agents or other drugs with antiparasitic or antiviral activity, both in separate forms and in a single dosage form.
• active ingredients such as, for example, anticancer agents or other drugs with antiparasitic or antiviral activity, both in separate forms and in a single dosage form.
• the compounds according to the present invention are useful as medicaments with anticancer activity, e.g.
• One of the advantages afforded by the compounds according to the present invention is the combination of antitopoisomerase activity, proper to the camptothecin portion of the molecule, and the integrin inhibiting activity, provided by the cyclopeptide portion of the molecule.
• the cyclopeptide portion containing the Arg- Gly-Asp sequence, not only directs the molecule against tumours expressing integrins, but, once the target has been reached, is capable of exerting multiple functions, ranging from the internalisation of the cytotoxic portion of the molecule to integrin inhibiting activity, with the resulting advantages, particularly in terms of the inhibition of tumour angiogenesis.
• the cyclopeptide portion, once separated from the camptothecin portion is also capable of exerting its action at a distance from the site of the tumour, and therefore the compounds according to the present invention also prove useful in the prevention or treatment of metastatic forms.
• the medicaments which are the subject of the present invention can also be used in the treatment of parasite diseases.
• Aad aminoadipic acid
• Boc ter-butoxycarbonyl
• CSA camphosulfonic acid
• NMP N-methyl-pyrrolidone
• TBTU tetrafluoroborate-O-benzotriazol-l-yl-tetramethyluronium
• TFA trifluoroacetic acid
• the linear peptide was synthesized in solid phase as described in example 1, inserting Fmoc-N-Me-Phe-(4-Pht-N-CH 2 )-COOH as the third amino acid, prepared as described above.
• the deprotections of N-Fmoc-terminal on resin were carried out with 30% diisopro- pylamine (300 eq) in solution in DMF (owing to the presence of phthalimide).
• 500 mg of the peptide were dissolved hot in 10 ml of absolute EtOH, to which 0.9 ml of a solution of NH 2 - NH 2 ⁇ 2 O 1 M in ethanol was added.
• the crude product was recovered by evaporating the organic phase and purified by flash chromatography (mobile phase: CHC -MeOH 7:3 + 1% AcOH); the fractions containing the product were pooled, washed with water, dehydrated and brought to dryness, and yielded a residue of 157 mg of pure product.
• the intermediate [N-Boc] -protected product showed the following experimental data:
• the benzylester was hydrogenolysed with H2/10%Pd-C at 20 psi with a yield of 70% after purification with CH 2 Cl 2 /MeOH 94:6.
• Example 10 was carried out exactly as described above and the conjugation between protected ST2581 and the camptothecin derivative ST3240 prepared in Example 8bis gave the compound named ST3241, having the following properties:
• the purified ⁇ ⁇ 3 receptor (Chemicon, cat. CC1020) was diluted in buffer (20 mM Tris, pH 7.4, 150 mM NaCl, 2 mM CaCl 2 , 1 M MgCl 2 , 1 mM MnCl2) at a concentration of 0.5 ⁇ g/ml. An aliquot of 100 ⁇ l was added to 96-well plates and incubated overnight at +4°C.
• the purified ⁇ v ⁇ receptor (Chemicon, cat. CC1020) was diluted in buffer (20 mM Tris, pH 7.4, 150 mM NaCl, 2 mM CaCl 2 , 1 mM MgCl 2 , 1 mM MnC ) at a concentration of 1 ⁇ g/ml. An aliquot of 100 ⁇ l was added to 96-well plates and incubated overnight at +4°C. Plates were washed once with buffer (50 mM Tris, pH 7.4, 100 mM NaCl, 2 mM CaC , 1 mM MgG , 1 mM MnCk, 1% bovine serum albumin) and then incubated for another 2 hours at room temperature.
• buffer 50 mM Tris, pH 7.4, 100 mM NaCl, 2 mM CaC , 1 mM MgG , 1 mM MnCk, 1% bovine serum albumin
• the affinity of the products for vitronectin receptors was expressed as IC50 value ⁇ SD, i.e. as the concentration capable of inhibiting 50% of the specific radioligand-receptor binding.
• IC50 value was elaborated using "ALLFIT" software.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Veterinary Medicine (AREA)
• General Health & Medical Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Public Health (AREA)
• Medicinal Chemistry (AREA)
• Animal Behavior & Ethology (AREA)
• Chemical & Material Sciences (AREA)
• Engineering & Computer Science (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Organic Chemistry (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Epidemiology (AREA)
• Molecular Biology (AREA)
• Oncology (AREA)
• Tropical Medicine & Parasitology (AREA)
• Virology (AREA)
• Communicable Diseases (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Peptides Or Proteins (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Nitrogen Condensed Heterocyclic Rings (AREA)

Priority Applications (7)

Applications Claiming Priority (2)

Publications (2)

Family

ID=35124307

Family Applications (1)

Country Status (12)

Cited By (2)

Families Citing this family (2)

Family Cites Families (4)

• 2004
  • 2004-05-13 IT IT000241A patent/ITRM20040241A1/it unknown
• 2005
  • 2005-05-04 BR BRPI0511037-8A patent/BRPI0511037A/pt not_active IP Right Cessation
  • 2005-05-04 EP EP05743015A patent/EP1747019A2/en not_active Withdrawn
  • 2005-05-04 TW TW094114403A patent/TW200538125A/zh unknown
  • 2005-05-04 WO PCT/IT2005/000261 patent/WO2005110487A2/en not_active Ceased
  • 2005-05-04 CN CNA2005800152323A patent/CN101010103A/zh active Pending
  • 2005-05-04 CA CA002562572A patent/CA2562572A1/en not_active Abandoned
  • 2005-05-04 JP JP2007512735A patent/JP2007537244A/ja not_active Withdrawn
  • 2005-05-04 MX MXPA06012886A patent/MXPA06012886A/es not_active Application Discontinuation
  • 2005-05-04 US US11/596,189 patent/US20070232639A1/en not_active Abandoned
  • 2005-05-04 AU AU2005243834A patent/AU2005243834A1/en not_active Abandoned
  • 2005-05-12 AR ARP050101933A patent/AR049275A1/es unknown

Also Published As

Similar Documents

Legal Events